Ipilimumab in Extensive Stage Small Cell Lung Cancer

Drug class Target Agent Diseases Line of Therapy Status Source
CTLA-4 inhibitors, Immunotherapy, Monoclonal antibody CTLA-4 ipilimumab (Yervoy) small cell lung cancer metastatic Trials complete with results Reck et al. 2013; Antonia et al. 2015

The efficacy and safety of CTLA-4 inhibitors for the treatment of patients with small cell lung cancer (SCLC) is currently under investigation. Ipilimumab has shown potential in treating patients with extensive SCLC in a phase II trial (NCT00527735; Reck et al. 2013).

In a phase I/II study comparing treatment with nivolumab alone andversus nivolumab in combination with ipilimumab in patients with recurrent SCLC, the combination arm demonstrated higher response rates than the single agent arm (CA209-032; Antonia et al. 2015).


Reference Study Type / Phase Line of Treatment Treatment Agent # Patients in Study Response Rate PFS (months) OS (months)
Reck et al. 2013 Phase II 1st line concurrent ipilimumab + carboplatin + paclitaxel 43 33% 3.9 9.1
phased ipilimumab + carboplatin + paclitaxel 42 57% 5.2 12.5
carboplatin + paclitaxel 45 49% 5.2 10.5
Antonia et al. 2015 (CA209-032) Phase I/II 2nd line nivolumab 40 15%    
nivolumab + ipilimumab 35 25%    
NOTE: OS = overall survival; PFS = progression-free survival


Contributors: Wade T. Iams, M.D., Douglas Johnson, M.D., Christine M. Lovly, M.D., Ph.D.

Suggested Citation: Iams, W.T., D. Johnson, C. Lovly. 2015. Immunotherapy in Cancer. My Cancer Genome http://www.padiracinnovation.org/content/molecular-medicine/c2654-small-cell-lung-cancer/ (Updated September 3).

Last Updated: September 24, 2015

Disclaimer: The information presented at padiracinnovation.org is compiled from sources believed to be reliable. Extensive efforts have been made to make this information as accurate and as up-to-date as possible. However, the accuracy and completeness of this information cannot be guaranteed. Despite our best efforts, this information may contain typographical errors and omissions. The contents are to be used only as a guide, and health care providers should employ sound clinical judgment in interpreting this information for individual patient care.